Dr. Berdeja on FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma

Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of frontline daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of frontline daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

Related Content:

Sarah Cannon Research InstituteOncLive TVMultiple Myeloma
Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.
Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma
Dr Leslie on the 5-Year Follow-Up of the ZUMA-5 Trial in R/R Indolent NHL